How can low‑grade glioma be distinguished from oligodendroglioma and dysembryoplastic neuroepithelial tumor on imaging?

Distinguishing Low-Grade Glioma, Oligodendroglioma, and DNET on Imaging

DNETs are distinguished from low-grade gliomas and oligodendrogliomas by their characteristic cortical location (especially temporal lobe), hypodense CT appearance with T1-hypointense/T2-hyperintense multicystic pattern, absence of perilesional edema and mass effect, and frequent calcification with possible overlying skull remodeling 1, 2.

Key Imaging Features by Tumor Type

DNET (Dysembryoplastic Neuroepithelial Tumor)

Location & Morphology:

• Predominantly temporal lobe (mesial or lateral), though can occur in insular cortex, frontal, occipital lobes 1
• Cortical-subcortical location with superficial involvement
• Approximately 40% are cystic with solitary nodular, multinodular, or diffuse forms 1
• Focal thinning or remodeling of overlying skull may be present 3

Signal Characteristics:

• CT: Hypodense 1
• MRI T1: Decreased signal (hypointense) 1, 2
• MRI T2/FLAIR: Hyperintense 1, 2
• Critical distinguishing feature: NO perilesional edema and NO mass effect 1, 2
• Contrast enhancement may be present but without mass effect 2

Associated Features:

• 30% associated with subtle cortical dysplastic changes in adjacent cortex 1
• Calcification common 2

Oligodendroglioma

Location & Morphology:

• Cortical-subcortical location, most commonly frontal lobe 3
• Superficial location may cause focal skull thinning/remodeling 3

Signal Characteristics:

• Heterogeneous signal intensity, particularly on T2-weighted imaging 3
• Calcification is a hallmark feature (better seen on CT) 3
• Minimal to moderate enhancement is common, even in low-grade tumors 3
• Indistinct tumor margins 3
• Perfusion may be moderately increased 3

Molecular Signature:

• Defined by 1p/19q codeletion plus IDH mutation 4, 5

Low-Grade Astrocytoma (IDH-mutant)

Molecular Features:

• IDH mutation present 4, 5
• Loss of nuclear ATRX expression 5
• Lacks 1p/19q codeletion 5

Imaging Characteristics:

• Generally less calcification than oligodendroglioma
• More homogeneous appearance than oligodendroglioma 3
• Typically less enhancement than oligodendroglioma in low-grade forms

Advanced Imaging Techniques for Differentiation

MR Spectroscopy

Critical for distinguishing DNET from low-grade gliomas 6:

• Low-grade gliomas: Marked loss of NAA (-72% ± 15%) and pronounced increase in Cho (117% ± 56%) 6
• DNETs (FCDMs): Less pronounced NAA loss (-29% ± 22%) and minimal Cho increase (21% ± 66%) 6
• NAA and Cho changes are more informative than metabolite ratios 6
• Can help differentiate astrocytomas from oligodendrogliomas 6

Perfusion Imaging

• Oligodendrogliomas: Mildly increased perfusion even in low-grade forms 3
• DNETs: Generally minimal perfusion increase 2
• DSC-MRI useful for grading and molecular marker prediction 7

Diffusion Imaging

• Combined with perfusion and spectroscopy, can predict IDH mutation and 1p19q deletion status 7, 2

Clinical Context Clues

DNET-Specific Presentation:

• Drug-resistant epilepsy in children/young adults 1, 2
• Partial seizures with or without secondary generalization 8
• No neurological deficit or stable congenital deficit 8
• Normal life expectancy if properly managed 8

Oligodendroglioma:

• Adults, typically 4th-5th decade
• Better prognosis with 1p/19q codeletion 9

Common Pitfalls

Critical Warning: Stereotactic biopsy alone is NOT recommended for suspected DNET, as sampling may yield only oligodendroglial components leading to misdiagnosis as oligodendroglioma 1. The specific glioneuronal elements diagnostic of DNET may be missed 1.

Contrast enhancement in DNET does not indicate malignancy if there is no mass effect or edema 2, 8. However, new enhancement in a previously non-enhancing lesion warrants concern 1.

Oligodendrogliomas commonly show enhancement even when low-grade, complicating differentiation from anaplastic forms 3. High growth rate and new enhancement suggest malignant transformation 3.

Diagnostic Algorithm

1. Assess location: Temporal cortical → favor DNET; Frontal cortical → consider oligodendroglioma
2. Evaluate mass effect and edema: Absent → strongly favor DNET; Present → favor glioma
3. Check for calcification on CT: Present in both DNET and oligodendroglioma
4. Assess signal heterogeneity: Heterogeneous T2 → favor oligodendroglioma; Multicystic → favor DNET
5. Perform MR spectroscopy: Marked NAA loss + high Cho → glioma; Mild changes → DNET 6
6. Evaluate perfusion: Increased → favor oligodendroglioma; Minimal → favor DNET
7. Clinical context: Drug-resistant epilepsy in young patient with no deficit → DNET

Definitive diagnosis requires histopathology with molecular testing (IDH, 1p/19q, FGFR1, BRAF) 4, 5, 2, 10.